"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
Adverse reactions with the use of LUFYLLIN (dyphylline) have been infrequent, relatively mild, and rarely required reduction in dosage or withdrawal of therapy.
The following adverse reactions which have been reported with other xanthine bronchodilators, and which have most often been related to excessive drug plasma levels, should be considered as potential adverse effects when dyphylline is administered:
Read the Lufyllin (dyphylline) Side Effects Center for a complete guide to possible side effects
Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported. This should be considered whenever these agents are prescribed concomitantly.
Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline (see Clinical PHARMACOLOGY ).
Read the Lufyllin Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 1/20/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Lufyllin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.